Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status

BACKGROUND: Patients with non-dialysis-dependent chronic kidney disease (ND-CKD) often receive an erythropoiesis-stimulating agent (ESA) and oral iron treatment. This study evaluated whether a switch from oral iron to intravenous ferric carboxymaltose can reduce ESA requirements and improve iron sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Toblli, Jorge Eduardo, Di Gennaro, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415953/
https://www.ncbi.nlm.nih.gov/pubmed/25928811
http://dx.doi.org/10.1371/journal.pone.0125528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415953/
https://www.ncbi.nlm.nih.gov/pubmed/25928811
http://dx.doi.org/10.1371/journal.pone.0125528

Ejemplares similares